| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
33,620,000 |
| Market
Cap: |
110.27(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.295 - $6.09 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aquestive Therapeutics is a pharmaceutical company. Co. is developing orally administered products to deliver various molecules using its proprietary technologies, PharmFilm®. Co.'s products within its central nervous system portfolio, focused on epilepsy, include: Sympazan®, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome; and Libervant™, a buccally, or inside of the cheek, administered soluble film formulation of diazepam, used as an alternative to device-dependent rescue therapies, available to patients with refractory epilepsy, which are a rectal gel and nasal sprays.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
158,668 |
| Total Buy Value |
$0 |
$0 |
$0 |
$151,571 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
75,000 |
75,000 |
75,000 |
75,000 |
| Total Sell Value |
$429,685 |
$429,685 |
$429,685 |
$429,685 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
2 |
2 |
2 |
2 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-11-30 |
4 |
D |
$8.59 |
$61,650 |
D/D |
(7,177) |
1,016,624 |
|
- |
|
| Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
1,023,801 |
|
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-11-30 |
4 |
D |
$8.59 |
$61,650 |
D/D |
(7,177) |
628,534 |
|
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
635,711 |
|
- |
|
| Braender Lori J |
General Counsel |
• • – |
2018-11-27 |
4 |
B |
$10.57 |
$10,570 |
D/D |
1,000 |
1,000 |
0.01 |
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-11-27 |
4 |
B |
$9.87 |
$9,870 |
D/D |
1,000 |
621,139 |
0.01 |
- |
|
| Wood Theresa |
SVP-HR and Org. Development |
• • – |
2018-11-26 |
4 |
B |
$10.34 |
$5,170 |
D/D |
500 |
79,765 |
0.01 |
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-11-23 |
4 |
B |
$9.90 |
$19,305 |
D/D |
1,950 |
620,139 |
0.01 |
- |
|
| Marshall Ken W. |
Commercial Leader |
• • – |
2018-11-21 |
4 |
B |
$10.15 |
$14,667 |
I/I |
1,445 |
1,445 |
0.01 |
- |
|
| Maxwell John T. |
SVP-Chief Financial Officer |
• • – |
2018-11-21 |
4 |
B |
$9.80 |
$98,000 |
D/D |
10,000 |
148,614 |
0.01 |
- |
|
| Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-11-21 |
4 |
B |
$10.25 |
$10,250 |
D/D |
1,000 |
1,009,229 |
0.01 |
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-11-21 |
4 |
B |
$10.17 |
$61,020 |
D/D |
6,000 |
618,189 |
0.01 |
- |
|
| Boyd Peter E. |
SVP-Operations/Value Delivery |
• • – |
2018-11-21 |
4 |
B |
$9.98 |
$1,996 |
D/D |
200 |
49,639 |
0.01 |
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-09-30 |
4 |
D |
$17.51 |
$2,837 |
D/D |
(162) |
1,008,229 |
|
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
1,008,391 |
|
- |
|
| Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-09-30 |
4 |
D |
$17.51 |
$2,837 |
D/D |
(162) |
1,008,229 |
|
- |
|
| Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
1,008,391 |
|
- |
|
| Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-08-31 |
4 |
D |
$18.01 |
$117,245 |
D/D |
(6,510) |
1,008,062 |
|
- |
|
| Schobel Alexander Mark |
Chief Innovation/Tech Officer |
• • – |
2018-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
1,014,572 |
|
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-08-31 |
4 |
D |
$18.01 |
$117,245 |
D/D |
(6,510) |
1,008,062 |
|
- |
|
| Kendall Keith J |
CEO and President |
• • – |
2018-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
1,014,572 |
|
- |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2018-07-24 |
4 |
B |
$15.00 |
$2,475,000 |
I/I |
165,000 |
165,000 |
1.5 |
- |
|
147 Records found
|
|
Page 6 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (1.86%) 
